sábado, 5 de noviembre de 2011

Press Announcements > FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation).

Atrial fibrillation occurs in more than 2 million Americans and is one of the most common types of abnormal heart rhythm. In atrial fibrillation, the beating of the heart’s two upper heart chambers (atria) is irregular and poorly coordinated. This leads to blood pooling in these chambers, resulting in blood clots. Non-valvular atrial fibrillation refers to atrial fibrillation in patients who do not have significant problems in their heart valves.
For more information please visit: Xarelto:
Press Announcements > FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm

No hay comentarios:

Publicar un comentario